ApoB48 Metabolism in Plasma and Interstitial Fluid

ApoB48IC2 Metabolism in Plasma and Interstitial Fluid

Sponsors

Lead Sponsor: Karolinska University Hospital

Source Karolinska University Hospital
Brief Summary

Postprandial increases in the levels of atherogenic chylomicron remnant lipoprotein particles have long been considered a presumable risk factor for the development of atherosclerosis with time, also in normolipidemic subjects. apoB-48 (Chylomicron) in blood is a specific marker for intestinal derived lipoproteins. Specific aim: To determine if apoB-48 containing lipoproteins may appear in IC in the postprandial state after a standard meal and investigate the effect fasting and feeding have on levels of lipids, apolipoproteins and the cholesterol component of lipoproteins in IF and plasma.

Methodology: Intercellular fluid will be collected using the cup technique. IF will be collected in intervals corresponding to different periods after food intake. The IF from these different occasions will then be analysed and compared using FPLC and Elisa.

Overall Status Recruiting
Start Date April 17, 2019
Completion Date December 31, 2021
Primary Completion Date June 1, 2020
Study Type Observational
Primary Outcome
Measure Time Frame
ApoB48 levels in blood and interstitial fluid 7 hours
Enrollment 10
Condition
Eligibility

Sampling Method: Non-Probability Sample

Criteria:

Inclusion Criteria:

- Over 18 years.

- For the T2D study group: Diagnosed with type 2 diabetes.

Exclusion Criteria:

For subjects with type 2 diabetes:

- Systemic inflammatory disease that requires active treatment

- Thyroid disease that requires active treatment

- Skin disease that requires active treatment and causes significant changes in the area of the skin that is to be investigated

- Treatment with oral glucocorticoids

- Levels of SR, TSH, T4 or Hemoglobin in the blood pronouncedly outside the reference range

- Pregnancy

For healthy controls:

- Registered disease in the health declaration that requires continuous systemic treatment. Exception to the above: well controlled hypertension in which case the subject should not have treatment with more than one antihypertensive drug, the drug must not be an alpha-blocker or beta-blocker or thiazide diuretic

- Skin disease that requires active treatment and causes significant changes in the area of the skin that is to be investigated

- Blood pressure pronouncedly above 140/90

- Blood test results pronouncedly outside the reference range

- Pregnancy

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Mats Rudling Principal Investigator Karolinska Institutet
Overall Contact

Last Name: Mats Rudling

Phone: +46 8585 869 55

Email: [email protected]

Location
Facility: Status: Contact: Patient research centre, Clinic of endocrinology, Karolinska University Hospital Viveca Åberg [email protected]
Location Countries

Sweden

Verification Date

April 2019

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Karolinska University Hospital

Investigator Full Name: Mats Rudling

Investigator Title: Professor

Has Expanded Access No
Condition Browse
Arm Group

Label: Type 2 diabetes patients

Label: Healthy controls

Study Design Info

Observational Model: Case-Control

Time Perspective: Other

Source: ClinicalTrials.gov